DE69832695T2 - Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit - Google Patents

Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit Download PDF

Info

Publication number
DE69832695T2
DE69832695T2 DE69832695T DE69832695T DE69832695T2 DE 69832695 T2 DE69832695 T2 DE 69832695T2 DE 69832695 T DE69832695 T DE 69832695T DE 69832695 T DE69832695 T DE 69832695T DE 69832695 T2 DE69832695 T2 DE 69832695T2
Authority
DE
Germany
Prior art keywords
flurbiprofen
salt
nsaid
nsaids
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69832695T
Other languages
German (de)
English (en)
Other versions
DE69832695D1 (de
Inventor
J. William WECHTER
D. John McCRACKEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/814,490 external-priority patent/US6160018A/en
Application filed by Loma Linda University filed Critical Loma Linda University
Application granted granted Critical
Publication of DE69832695D1 publication Critical patent/DE69832695D1/de
Publication of DE69832695T2 publication Critical patent/DE69832695T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69832695T 1997-03-10 1998-03-04 Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit Expired - Lifetime DE69832695T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/814,490 US6160018A (en) 1995-03-13 1997-03-10 Prophylactic composition and method for alzheimer's Disease
US814490 1997-03-10
PCT/US1998/004176 WO1998040061A1 (en) 1997-03-10 1998-03-04 Use of r-nsaid's for the prevention of alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69832695D1 DE69832695D1 (de) 2006-01-12
DE69832695T2 true DE69832695T2 (de) 2006-09-14

Family

ID=25215202

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69832695T Expired - Lifetime DE69832695T2 (de) 1997-03-10 1998-03-04 Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
DE69841267T Expired - Lifetime DE69841267D1 (de) 1997-03-10 1998-03-04 Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69841267T Expired - Lifetime DE69841267D1 (de) 1997-03-10 1998-03-04 Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit

Country Status (9)

Country Link
EP (2) EP0966277B1 (enExample)
JP (1) JP2001514655A (enExample)
AT (2) ATE311865T1 (enExample)
AU (1) AU6682298A (enExample)
CA (1) CA2283255C (enExample)
DE (2) DE69832695T2 (enExample)
DK (1) DK0966277T3 (enExample)
ES (1) ES2253810T3 (enExample)
WO (1) WO1998040061A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163986B1 (es) * 1999-07-13 2003-02-16 Menarini Lab Acidos-alfa-arilpropionicos y arilaceticos como inhibidores de la ciclooxigenasa-ii.
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
EP1558268A4 (en) * 2002-09-17 2008-09-17 Univ New York METHODS FOR TREATING AGE-RELATED MEMORY ALTERATIONS (AAMI), LIGHT COGNITIVE DEFICITS (MCI) AND DEMENTIA USING CELL CYCLE INHIBITORS
EP1551384A4 (en) * 2002-10-07 2008-04-09 Encore Pharmaceuticals Inc R-NSAID ESTERS AND ITS USE
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
WO2008149181A1 (en) 2007-06-04 2008-12-11 Techfields Inc Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
WO2010065936A1 (en) 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
CN104540504A (zh) 2012-01-18 2015-04-22 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
EP3022560B1 (en) 2013-07-11 2020-09-02 University of North Texas Health Science Center at Fort Worth Blood-based screen for detecting neurological diseases in primary care settings
JP6364488B2 (ja) 2013-11-26 2018-07-25 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワースＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ Ａｔ Ｆｏｒｔ Ｗｏｒｔｈ 認知欠損を治療するための個別化医療的手法
AU2019209792B2 (en) * 2018-01-18 2025-08-14 University Of North Texas Health Science Center At Fort Worth Companion diagnostic for NSAIDs and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease
US20230038360A1 (en) * 2019-12-20 2023-02-09 Basf Se Composition for the treatment of amyloid-beta associated diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
FR2687915B1 (fr) * 1992-02-28 1995-05-05 Rhone Poulenc Rorer Sa Composition pharmaceutique utilisable comme analgesique contenant l'acide (benzoyl-3 phenyl)-2 propionique-(r).
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
AU3641597A (en) * 1996-06-21 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions comprising r-ibuprofen

Also Published As

Publication number Publication date
ATE311865T1 (de) 2005-12-15
DE69841267D1 (de) 2009-12-10
ATE446748T1 (de) 2009-11-15
AU6682298A (en) 1998-09-29
EP1642575B1 (en) 2009-10-28
CA2283255A1 (en) 1998-09-17
EP1642575A1 (en) 2006-04-05
EP0966277B1 (en) 2005-12-07
DK0966277T3 (da) 2006-03-27
JP2001514655A (ja) 2001-09-11
ES2253810T3 (es) 2006-06-01
DE69832695D1 (de) 2006-01-12
WO1998040061A1 (en) 1998-09-17
CA2283255C (en) 2007-01-02
EP0966277A1 (en) 1999-12-29

Similar Documents

Publication Publication Date Title
DE69634776T2 (de) Verwendung eines r-nsaid als chemoschützendes mittel zur behandlung von colorektalkrebs
DE69832695T2 (de) Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
US6160018A (en) Prophylactic composition and method for alzheimer's Disease
Dodd et al. Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
AU2018203357B2 (en) New methods
US5981592A (en) Method and composition for treating cystic fibrosis
EP1696904B1 (de) Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes
DE69309492T2 (de) Antipyretische und analgetische zusammensetzungen, die optisch reines r-ketorolac enthalten
EP2892518B1 (en) Compositions for treating parkinson's disease
NZ251138A (en) R(-) ketoprofen composition; analgesic composition contains pure r(-) stereoisomer
KR20110071050A (ko) 알츠하이머 질환 및 관련 장애의 치료를 위한 조니사미드 및 아캄프로세이트의 조합 조성물
CN116712423A (zh) 治疗特定患者群体的神经变性病症的方法
DE69328838T2 (de) Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
IL261669B1 (en) A combination of thyroid hormones and a rxr agonist for the treatment of autoimmune diseases
DE3390114C2 (enExample)
RU2623062C2 (ru) Новая терапия транстиретин-ассоциированного амилоидоза
Karavokiros et al. Flumazenil: a benzodiazepine antagonist
DE10047319A1 (de) Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
EP1154766B1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können
US20110118317A1 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
Kuhn et al. Pharmacology and hypnogenic properties of brotizolam in animals.
JP2022511755A (ja) 精神障害の治療のためのガボキサドールとリチウムとの組み合わせ
JP2002541224A (ja) うつ病の治療のためのｇａｂａ類縁体と三環系化合物の組合わせ
KR20250173974A (ko) 엠파글리플로진 및 텔미사르탄을 함유하는 대사이상 관련 지방성 간질환 예방 또는 치료용 약학적 조성물
Kamath Study of Anticonvulsant Effect of Simvastatin in Maximal Electroshock and Pentylenetetrazole Induced Seizure Model in Albino Mice

Legal Events

Date Code Title Description
8364 No opposition during term of opposition